UBC and acute myeloid leukemia: Similarly, when WT recipient mice were transplanted with Rnpc3lox/−;UBC-CreERT2 AML cells and treated with TMX, the median survival of these mice was extended by 55% (34 d compared to 22 d; Fig. 4F).